After decades since the discovery of natural killer (NK) cells as potential effector cells fighting malignantly transformed and virally infected cells, little progress has been made in their clinical application. This yet unrealized therapeutic effect is presumably, at least in part, due to low numbers of functional NK cells that could be obtained from the peripheral blood relative to tumor burden. Our group hypothesized that a relatively small NK cell number to targeted malignant cells is the cause of a lack of clinical effect. We pursued obtaining large numbers of NK cells via ex vivo expansion using feeder cells that express membrane-bound IL-21. Early clinical studies demonstrate safety of administration of ex vivo expanded NK cells after transplantation using this method and suggest a therapeutic benefit in terms on decreasing relapse rate and possible control of viral infections post-transplant can be achieved. Successful application of NK cells after hematopoietic stem cell transplantation opens the possibility to effectively enhance the anti-tumor effect and decrease relapse rate post-transplant. Moreover, high doses of NK cells could prove more efficacious in enhancing anti-tumor effects, not only in hematological malignancies, with our without transplantation, but also in solid tumor oncology.
transplanted with an HLA-matched donor for HLA-A, HLA-B, HLA-C, -DR ± DQ loci. The anti-tumor effect after transplant depends mainly on allogeneic T cell-mediated anti-tumor responses. Transplanting over HLA barriers has shown, in case of KIR-ligand mismatch, to induce NK cell activation. This concept was first described in 2002 by Ruggeri et al. who showed that patients with acute myeloid leukemia (AML) receiving a KIR-mismatched haploidentical stem cell transplantation showed drastic increase in five-year relapse-free survival compared to patients without a KIR mismatch (100% vs. 25%) [5] . After this report, haploidentical transplantation has been exploited in different hematological diseases, using different conditioning regimens, GvHD prophylaxis and stem cell sources. Results from these studies have been conflicting, and high incidence of GvHD as well as opportunistic infections has been a major concern [6, 7] . Optimization of the haploidentical transplantation protocols, recently by application of post-transplantation cyclophosphamide (PTCy) as the most widely used method [8, 9] , has led to improved transplant outcomes in terms of safety and decreased transplant-related mortality (TRM) with outcomes similar to HLA-matched transplants. As these major drawbacks are at least partially resolved, the focus has shifted to disease relapse, which has emerged the most common cause of treatment failure, not only after HLA-matched transplants but also after haploidentical transplantation.
First results from studies investigating the effect of KIR-ligand mismatch versus non-KIR-mismatched in the PTCy setting are disagreeing. While Symons and colleagues showed that recipients of an inhibitory KIR-genemismatched graft had lower relapse rate and improved survival and that patients with KIR Bx donor for recipients with homozygous A haplotype had improved non-relapse mortality and survival [10] , Hosokai et al. reported that KIR Bx donors for recipients with A/A haplotype had higher incidence of acute GVHD with no impact on non-relapse mortality, relapse or survival [11] . Low NK cell numbers and function early after transplantation have been observed related to the PTCy administration [12, 13] , while higher numbers of NK cells have been associated with better transplant outcomes [8] [9] [10] [11] . This association is true for both allogeneic and autologous transplantation [14] [15] [16] [17] . Although the NK cells are about the first cells that can be detected in the peripheral blood after transplantation, their phenotype and function are immature [13] . It takes at least 3-6 months until these cells gain KIR expression and become functionally active to induce optimal anti-leukemia responses. To warrant early post-transplant graft-versus-leukemia effects-when tumor load is low-it seems essential to improve NK cell repopulation, which can be accomplished by post-transplant NK cell transfer.
NK cell expansion
Different sources of NK cells are used for NK cell therapy. Autologous as well as allogeneic NK cells can be purified from peripheral blood apheresis products or obtained from umbilical cord blood (UCB) [18, 19] . Additionally, NK cells can be developed from CD34 + UCB stem cells or from induced pluripotent stem cells [20, 21] . However, differences among NK cells obtained from these sources have not been adequately described.
Since progression-free survival after hematopoietic stem cell transplantation is positively correlated with the number of peripheral blood NK cells, it seems of importance to infuse high numbers of NK cells for NK cell therapy [22, 23] . NK cells make up only approximately 10% of mononucleated cells in the blood and even less in umbilical cord blood, while the number of NK cells that can be obtained via apheresis procedure on average 1-3 × 10 7 /kg of an adult individual, enough in general for 1 transfer dose only [24, 25] which makes NK cell expansion necessary. Different methods have been developed for NK expansion, both in vivo and ex vivo [25] .
Ex vivo expansion methods included single cytokines or cytokine cocktails containing IL-2, IL-15, IL-12 or IL-18 [18, 26] . To potentiate proliferation, anti-CD3 antibodies were added to cultures [27] . Also feeder cells are often used for NK cell proliferation. EBV-transfected cell lines, peripheral blood mononuclear cells, Wilms tumor-derived cell lines are used for this purpose [28, 29] . However, the most widely used feeder cell line is the chronic myeloid leukemia-derived cell line, K562. This cell line is either used in combination with different cytokines or transduced to express membrane-bound IL-15, IL-21 or 4-1BB (CD137) [30, 31] . Probably the best method of expansion so far, yielding high NK cell numbers, which uses K562 cells stable transfected with CD64, CD86, truncated CD19, 4-1BB and mbIL-21, has been developed by our group [32] . With this method, NK cell proliferation can continue for 8-10 weeks before NK cells go into senescence, with NK cells displaying longer telomeres and the capacity of continuous proliferating capacity. For UCB-derived NK cells, proliferation protocols are similar to those used for peripheral blood NK cell expansion and also consist of cytokine combinations in the presence or absence of different feeder cells expressing NK cell-activating ligands (membrane-bound cytokines, 4-1BB) and anti-CD3 antibodies [18, 33] .
In addition to ex vivo NK cell expansion, in vivo NK cell expansion has been investigated extensively. Expansion protocols depend mainly on cytokine infusion, of which IL-2 has been the most frequently used cytokine [34] . Increase in peripheral blood NK cells depends on both mature NK cell proliferation and induced NK cell development from bone marrow-derived stem cells [35] . Drawbacks of in vivo NK cell expansion protocols are side effects due to T cell activation, which are also sensitive to most cytokines used for NK cell activation. This makes the use of in vivo NK cell expansion after stem cell transplantation less appealing not only due to systemic adverse effects but also due to the possible risk of T cell-mediated GvHD.
Post-transplantation NK cell therapy
NK cell therapy has been first utilized in a non-transplant setting in hematological malignancies and solid tumors [36] . Although successes were limited to a minority of patients, NK cell infusion was demonstrated safe and feasible [34] . These results have led to exploit post-transplantation NK cell transfer in hematological malignancies to warrant early NK cell repopulation.
NK cell infusion after hematopoietic stem cell transplantation has been utilized in autologous and allogeneic transplantation studies. In a small study in AML patients with impending relapse, Uharek et al. showed favorable two-year survival (40% vs. 11%) when treated with a haploidentical transplantation in combination with post-transplant NK cell infusion, as compared to haploidentical transplantation alone. Also in multiple myeloma patients, NK cell were infused after both autologous and allogeneic transplantation [37, 38] with no safety concerns.
We recently reported on a phase I clinical study in highrisk myeloid leukemia patients treated with haploidentical transplants and multiple donor-derived, ex vivo expanded NK cell infusions using feeder cells expressing mbIL-21 [13] . In this dose escalation study, three doses of NK cells infused on Day-2, + 7 and + 28 (up to Day + 90), up to 1 × 10 8 /kg were safely infused without reaching a maximum tolerated dose and with no induction of grade 3 or 4 acute GvHD or higher TRM. In addition, a low incidence of CMV and BK virus reactivation was noted along with a lower than expected relapse rate for the high-risk patients treated on this study. Products were a highly pure collection of NK cells (average 99%). Infused NK cells had mature phenotype and were functionally active, holding the capacity to mediate anti-leukemia cytotoxic responses, and high IFN-γ and TNF alpha production. Out of 13 treated patients, 11 patients showed sustained remission, only one patient relapsed and another patient succumbed to infectious disease [13] . The patient who relapsed had very high risk of leukemia relapse (FLT3 + AML patient in CR2 with detectable minimal residual disease) and received the lowest dose of NK cells (1 × 10 5 /kg). These results encouraged us to further pursue this approach in a randomized study to confirm the ability of ex vivo expanded NK cells to decrease relapse rate post-transplant, as well as explore NK cell therapy in a non-transplant setting for both hematological malignancies and possibly solid tumors. A second generation, potentially safer NK cell product with similar characteristics, produced without K562 feeder cells, is currently being explored.
Future directions
Results from current studies with mbIL-21 ex vivo expanded NK cell infusions post-transplant are very promising and hold the exciting possibility for improvement in relapse rate post-transplant, which is urgently needed especially for patients with very high-risk or advanced hematological malignancies, for which relapse rate may exceed 50%. In addition, NK cell therapy could be utilized in patients with advanced or refractory leukemia with the goal of achieving remission and offer the chance for these patients to undergo transplantation. Moreover, due to the broad anti-tumor effect and safety profile as compared for antigen-specific therapy (antibody therapy, CAR-T cells, etc.), this therapy could potentially expand for a broad variety of malignancies and extend the therapeutic armamentarium for a large number of patients.
Expansion protocols yielding the highest NK cell numbers depend, as for now, on the use of feeder cells. Although the culture conditions have been standardized according to good manufacturing practices, the use of cancer cell lines for NK cell production and clinical applications is still controversial. Therefore, new feeder cell-free methods are under investigation and one very successful method, among others, is the use of particles prepared from plasma membrane of K562-MB21-41BBL cells that are derived from the previously described K562 cell line expressing 4-1BB and membrane-bound IL-21 (PM21 particles) [39, 40] , which yields high numbers of cytotoxic NK cells that home to different organ sites after infusion in NSG mice.
Since NK cell infusions seem to be safe and feasible, NK cell therapy could also be exploited in hematological malignancies other than myeloid leukemia and solid tumors. Although the number of treated patients with other malignancies is very small, solid tumors seem to be less susceptible to NK cell therapy; however, treatment successes have been reported. Tumor microenvironment plays a major role in damping the therapeutic effect in these diseases, warranting development of novel NK cell strategies that either boost NK cell activation or target the tumor microenvironment in these patients.
One of these strategies that boost NK cell activation is the use of antibody therapy. By expression of CD16 (Fc gamma RIII receptor) on the cell surface, NK cells are able to induce antibody-dependent cellular cytotoxicity (ADCC). In the last decade, many new tumor antigen-specific antibodies have been developed for immunotherapy. Examples are anti-Her2 for breast cancer, anti-EGFR for different epithelial tumors and anti-CD20 for lymphoma [41] [42] [43] . Since many of these enhance NK cell-mediated tumor cell killing, it can be envisioned to combine antibody treatment with NK cell therapy. As the field of antibody therapy is developing rapidly, bispecific NK cell-activating antibodies are also being developed [44] . These antibodies recognize NK cell-activating receptors as well as tumor-specific antigens, which brings the NK cell in close physical proximity with cancer cells, to possibly enhance anti-tumor effects in this setting.
Another approach to increase NK cell activation is the use of anti-KIR antibodies that block inhibitory KIRs on the surface of NK cells, thereby mediating an NK cell-activating signal. Although the NK cell inhibitory signal to normal self is blocked, NK cells do not attack healthy cells, since these cell lack expression of activating stress molecules. Anti-KIR antibodies are often used in combination with other immunotherapeutic strategies and have been proved save. Preclinical studies in lymphoma have shown induction of NK cell-mediated lymphoma cytotoxicity when the anti-KIR antibody lirilumab is combined with anti-CD20 antibody treatment [45] , and clinical studies are now being carried out (NCT01714739, NCT02481297).
The NK cell-mediated anti-tumor response could potentially be enhanced by transducing NK cells with a chimeric antigen receptor (CAR-NK), which recognizes tumor-specific antigens [46, 47] . The CAR is an artificially modified fusion protein that consists of an extracellular antigen recognition domain fused to an intracellular signaling domain. T cells transduced with CAR have been studied extensively, and the first CAR is now FDA approved for pediatric patients with CD19+ hematological malignancies. The potential advantage of CAR-NK cells over CAR-T cells is a more favorable safety profile, as their intrinsic mechanism of action prevents them for attacking non-cancerous cells, thereby preventing collateral damage. Moreover, CAR-NK cells could yield higher initial cytotoxicity and can be generated from different donors. However, they display low transfection efficiency and do not expand ex vivo [47] . Preclinical studies in hematological malignancies as well as in solid tumors have shown anti-tumor responses with either transduction of primary NK cells or of the NK-92 cell line [48] [49] [50] . Until now, only few phase I/II clinical studies are being carried out with CAR-NK cells (MUC1+ solid tumors NCT02839954, CD33+ acute myeloid leukemia NCT02944162, B-acute lymphoblastic leukemia NCT01974479) and results are eagerly awaited.
Methods for altering the tumor microenvironment are numerous and the use of checkpoint inhibitor is one of them. There is an increasing interest in combining NK cell therapy with checkpoint inhibitors. NK cells not only express receptors that ligate inhibiting molecules on the cancer cells but also have a role in paving the path for T cell tumor infiltration. The innate response is the initiator of chemokine and cytokine release responsible for T cell infiltration into the tumor microenvironment. Responsiveness to checkpoint inhibitors has been shown to be dependent on these infiltrates. Most interesting is combining NK cells with PD-1/ PDL-1 inhibitors, which already has been shown effective in myeloma and lymphoma [51, 52] . Effects partially depend on inhibition of NK cell blocking [53] .
Conclusions
Due to optimized haploidentical transplantation protocols, haploidentical stem cell transplantation for hematological malignancies has become a very attractive therapeutic option with outcomes similar to HLA-matched donors. As NK cell reconstitution post-transplant is suboptimal, it is likely that it contributes to suboptimal graft-versus-leukemia responses. As such, post-transplant NK cell administration has been of great interest. Administration of ex vivo expanded NK cells in the early post-transplant period not only has been shown to be safe and feasible, but also a very encouraging is the low relapse rate that has been noted, warranting a randomized study to confirm a possible therapeutic benefit. To enhance NK cell-mediated cytotoxicity with or without transplantation, a multitude of different approaches are of great interest for the foreseeable future, like combination with antibody therapy, checkpoint inhibition or CAR-NK cells, all of which hold the promise to make NK cell therapy a viable therapeutic approach for cancer therapy.
